Drugs / Conivaptan
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER | — | 2005-12-29 | fda.gov ↗ |
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03000283 | Mar 2017 → Feb 2019 | brain edema, intracerebral hemorrhage | Jesse Corry | Completed | No outcome recorded |
| Phase 1 | NCT01370148 | Apr 2011 → Feb 2014 | liver disorder | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00930202 | Aug 2009 → May 2010 | traumatic brain injury | University of Washington | Completed | No outcome recorded |
| Phase 1 | NCT00887627 | Apr 2009 → Jul 2010 | kidney disorder | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00851227 | Feb 2009 → Jan 2010 | liver disorder | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01954290 | Sep 2015 | brain edema, stroke disorder | University of Florida | Withdrawn | No outcome recorded |
| Phase 2 | NCT00592475 | Dec 2007 → Nov 2008 | cirrhosis of liver | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00057356 | Nov 2002 → Mar 2004 | heart failure | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT01451411 | Feb 2012 → Jan 2014 | — | Cumberland Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00843986 | Apr → Aug 2009 | heart failure | Cumberland Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00684164 | May 2008 → Nov 2009 | — | Columbia University | Withdrawn | No outcome recorded |
| Phase 3 | NCT00478192 | Apr 2007 → Aug 2008 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00379847 | Feb 2004 → Jun 2005 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00380575 | Aug 2000 → Feb 2003 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00492037 | Jan 2000 → Feb 2002 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT00727090 | Aug 2008 → Jan 2010 | — | Northwestern University | Terminated | No outcome recorded |
| Phase 4 | NCT00435591 | Jan 2007 → Sep 2008 | — | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00811486 | Jan 2009 → Jul 2010 | heart failure, pulmonary hypertension | University of Colorado, Denver | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT01752543 Comparator | Dec 2013 → Jun 2015 | heart failure | Finn Gustafsson | Completed | No outcome recorded |
| Phase 4 | NCT00806910 Comparator | Oct 2008 → Feb 2010 | heart failure | Albert Einstein Healthcare Network | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00924014 Comparator | Jul → Dec 2009 | heart failure | Hennepin County Medical Center, Minneapolis | Unknown | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Conivaptan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00924014 ↗ |
| Known as | CI-1025 | “A 4-Day, Double-Blind, Placebo-Controlled, Multicenter Study of IV YM087 (CI-1025) to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia” NCT00380575 ↗1“Oral YM087 (CI-1025)” NCT00492037 ↗ |
| Known as | Conivaptan hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1755 ↗ |
| Known as | conivaptan hydrochloride | “Drug: conivaptan hydrochloride” NCT01370148 ↗ |
| Known as | Vaprisol | “Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.” NCT00930202 ↗ |
| Known as | YM087 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00492037 ↗ |
| Action | Inhibit | “Vasopressin V1a receptor antagonist” CHEMBL1755 ↗ |
| Modality | Small molecule | “Conivaptan, a non-peptide vasopressin (AVP) receptor antagonist” PMID 32253717 ↗ May 2020 |
| Route | Intravenous | “IV YM087” NCT00380575 ↗ |
| Target | AVPR1A | “Vasopressin V1a receptor antagonist” CHEMBL1755 ↗ |
| Target | AVPR2 | “Vasopressin V2 receptor antagonist” CHEMBL1755 ↗ |